News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Bloomberg Law News Regulatory and legal
Black Diamond Therapeutics Inc. has settled a patent infringement lawsuit filed by HMI Medical Innovations LLC. HMI had alleged that Black Diamond's cancer therapy development infringed on six of its patents. The companies reached a confidential settlement and license agreement, leading to the dismissal of the lawsuit with prejudice.
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Stifel has reiterated its Buy rating for Black Diamond Therapeutics (BDTX.US) and maintained its target price at $8. This indicates the firm's continued positive outlook on the company's stock performance.
Black Diamond Therapeutics reported a Q2 2026 net loss of $9.9 million, or $0.17 per share, with a six-month net loss of $18.9 million, compared to a net income of $46.0 million in 2025 that included a $70.0 million Servier upfront payment. The company's …
Black Diamond Therapeutics, Inc. reported its second-quarter 2026 financial results, showing no license revenue, a net loss of ($9.91M), and a diluted loss per share of ($0.17). This represents an improvement compared to the prior-year quarter's net loss of ($10.56M) and ($0.19) diluted loss …
Black Diamond Therapeutics Inc (BDTX) has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters, provides an overview of the company's financial performance. For detailed information and full access to the report, users are directed to …
Black Diamond Therapeutics reported a narrower Q2 net loss of $9.91 million, down from $10.56 million in the prior year. The operating loss also decreased to $12.06 million due to a 10.16% reduction in total operating expenses. The company's cash and equivalents totaled $110.5 …
Black Diamond Therapeutics reported its Q2 2026 financial results, highlighting positive Phase 2 clinical trial results for silevertinib in non-classical EGFRm NSCLC patients. The company presented data showing strong clinical activity, durable responses, and significant brain penetration, with no new safety signals observed. Black …
Black Diamond Therapeutics, Inc. (BDTX) reported a second-quarter loss of $9.9 million, or 17 cents per share, which surpassed Wall Street expectations of an 18-cent loss. The company's shares were trading at $1.79 on Wednesday, down from $2.73 a year ago. The results were …
Black Diamond Therapeutics Inc (BDTX) is projected to report an earnings loss of 20 cents per share. This information comes from a Refinitiv earnings preview, indicating an upcoming financial announcement for the company. The full article content is behind a paywall on TradingView.
This article provides an overview of the market sentiment for Black Diamond Therapeutics (BDTX), including analyst consensus, short interest, options flow, and insider activity. Key signals indicate a "Buy" consensus from analysts with an average price target of $12, a significant short float of …
This article details the shareholder structure of Black Diamond Therapeutics Inc (BDTX), listing major individual and institutional holders, their proportional ownership, and recent changes in their holdings. It also categorizes shareholders by type (e.g., Investment Advisor, Venture Capital) and provides institutional shareholding trends over …
This article provides the quarterly and annual cash flow statements for Black Diamond Therapeutics Inc (BDTX), covering operating, investing, and financing activities. It presents detailed financial figures from FY2018Q3 through FY2026Q1, along with year-over-year percentage changes. The report also includes FAQs explaining the different …
This page provides the income statement for Black Diamond Therapeutics Inc (BDTX), offering quarterly and annual financial data spanning several years. It details revenue, operating expenses, research and development costs, operating profit, non-operating income/expenses, and net income, along with earnings per share. The document …
Black Diamond Therapeutics Inc. (BDTX) closed at $1.76, down 4.35%, with a market cap of $100.85 million. The company, a clinical-stage oncology firm, is developing MasterKey therapies targeting oncogenic mutations and has strong fundamentals despite recent stock price fluctuations. Analysts have a "Buy" rating …
This article provides a valuation analysis of Black Diamond Therapeutics Inc (BDTX), noting its current valuation score is 6.65, ranking it 310 out of 386 in the Biotechnology & Medical Research industry. The company's current P/E ratio is -2.31. Key financial ratios such as …
Search by ticker symbol or company name and select a result to open its chart.